Enrollees in silver plans through the exchanges could be paying more than twice as much on prescription drugs than they would under a typical employer plan, new research finds.

The report — commissioned by the Pharmaceutical Research and Manufacturers of America and conducted by actuarial firm Milliman — found exchange participants are paying a "far larger increase in out-of-pocket costs than was found for other medical care."

Overall, the report found that silver plan enrollees would likely pay 130 percent more for out-of-pocket prescription drugs compared to people on similar employer-sponsored plans.